Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Fempharma LLC currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is assigned to 1 distinct examiner, indicating a highly concentrated environment for the company. Olga V Tcherkasskaya serves as the busiest examiner for the portfolio, overseeing the current outstanding action. The interaction is further localized within a distinct art unit.
For a practitioner, this concentration means that the outcome of the entire pending portfolio rests on the decisions of the assigned official. There is no diversification of examiner perspectives across the current filings. The focus on the Biotechnology & Pharmaceuticals technology area suggests a specialized intellectual property strategy. Because only a distinct art unit is involved, the company may experience consistent examination standards across its pending matters.
This lack of variety in examiners can simplify communication but increases the impact of the assigned examiner's tendencies on the whole portfolio. Practitioners should prepare for a focused dialogue with the assigned official to navigate the specific requirements of the sector. Monitoring the specific allowance rates and procedural preferences of the assigned examiner is crucial when the portfolio is this narrow. Such a focused approach allows for a deep understanding of the examiner's concerns and may lead to more efficient prosecution if a positive relationship is established.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, HONG | 1 | 30.9% | +5.6% |
| TCHERKASSKAYA, OLGA V | 1 | 55.4% | +46.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18411193 | Pharmaceutical Composition and Method for Improving Biomechanical Integrity of the Pelvic Floor | TCHERKASSKAYA, OLGA V | 30d |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18622971 | Pharmaceutical Composition and Method for Treating or Preventing Candidiasis | YU, HONG | 1614 | §103§112 | Final Rejection | 22d | Pending | Mar 31, 2024 |
| 18411193 | Pharmaceutical Composition and Method for Improving Biomechanical Integrity of the Pelvic Floor | TCHERKASSKAYA, OLGA V | 1615 | §112 | Final Rejection | 30d | Pending | Jan 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial